The market for follow-on biologics: how will it evolve?
Health Aff (Millwood)
; 25(5): 1291-301, 2006.
Article
in En
| MEDLINE
| ID: mdl-16966725
ABSTRACT
With spending on biologics rising and patent expiry approaching for several blockbuster biologics, Congress and the Food and Drug Administration are considering creating a clear pathway for so-called follow-on biologics. Differences between drugs and biologics will affect market outcomes in various ways. Conservative budget impacts are appropriate in the short run because fewer competitors will enter, and average prices will drop less than was the case following the Hatch-Waxman Act. Over the long term, intellectual property provisions will be important considerations for policymakers designing a pathway for follow-on biologics that balances price competition and innovation incentives.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Products
/
Biotechnology
/
Drug Industry
/
Health Policy
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Health Aff (Millwood)
Year:
2006
Document type:
Article
Affiliation country:
United States